Oral Intradialytic Amino Acids Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis (OASIS)
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
The study will test and compare the efficacy of a single essential amino acid valine with a combination of essential amino acids (EAA) supplement on fatigue, frailty, and cognitive function in end-stage kidney disease (ESKD) patients undergoing hemodialysis (HD) treatment.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 64
Healthy Volunteers: f
View:
• Male or Female
• Age 18-64 years
• Receiving 3 x weekly in clinic hemodialysis for at least 6 months
Locations
United States
Texas
The University of Texas Health Science Center at San Antonio
RECRUITING
San Antonio
Contact Information
Primary
Subrata Debnath, PhD
nath@uthscsa.edu
210-567-4700
Time Frame
Start Date: 2024-10-18
Estimated Completion Date: 2026-03
Participants
Target number of participants: 28
Treatments
Experimental: Treatment group Valine then EEA
Valine will be administered as two 4 gm packets administered on dialysis treatment day followed by a washout period and then EEA
Experimental: Treatment group EEA then Valine
EAA will be administered as one 12.5 gm packet administered on dialysis treatment day followed by a washout and then Valine
Related Therapeutic Areas
Sponsors
Collaborators: National Center for Advancing Translational Sciences (NCATS), IIMS-UT Health San Antonio
Leads: The University of Texas Health Science Center at San Antonio